FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2574201053> ?p ?o ?g. }

• W2574201053 abstract "Abstract Abstract 1022 Background: Neutropenic complications represent important dose-limiting toxicities of cancer chemotherapy. We recently developed and validated a risk model for neutropenic complications in patients with solid tumors or lymphoma receiving cancer chemotherapy (Lyman et al. Cancer 2011). While practice guidelines recommend primary colony-stimulating factor (CSF) prophylaxis for patients at >20% risk of febrile neutropenia (FN), many patients receive chemotherapy regimens associated with an intermediate risk (10–20%) of FN. For these patients, the decision to give or withhold primary CSF prophylaxis is based on clinical judgment. We report here the ability of the risk model to identify patients with individual characteristics placing them at high risk for neutropenic complications among patients receiving intermediate risk chemotherapy regimens. Methods: A prospective cohort study was conducted of consenting patients initiating a new chemotherapy regimen at 115 randomly selected US oncology practices between 2002–2006. The risk of cycle 1 severe or febrile neutropenia was estimated [95% CI] utilizing logistic regression analysis adjusting for key clinical factors including: planned chemotherapy, prior chemotherapy, age, abnormal hepatic or renal function, low pretreatment white blood count, and immunosuppressive medications. The cumulative incidence of severe neutropenia and FN across 4 cycles was estimated by the product limit method of Kaplan and Meier. Results: Among 3,760 patients with cancers of breast, lung, ovary, colon, or lymphoma, 2,270 received an intermediate risk chemotherapy regimen based on NCCN guidelines. Overall, in the subpopulation receiving intermediate risk regimens, severe or febrile neutropenia occurred in cycle 1 in 21.4% while FN over 4 cycles was observed in 11%, and primary CSF prophylaxis was utilized in 16.4%. The performance of the risk model was good in this subgroup with a c-statistic of 0.82 [0.80–0.84]. Among the half of patients classified as high risk based on the model despite receiving an intermediate risk chemotherapy regimen, cycle 1 severe or febrile neutropenia occurred in 38% [35%–41%] compared to 5% [4%–6%] of patients classified as low risk based on the model receiving such regimens. Model sensitivity and specificity were 89% and 61%, respectively. The cumulative risk of FN over 4 cycles of chemotherapy was 20% in predicted high risk group versus 5% in the low risk group (Figure). The majority of severe or febrile neutropenia events (67%) and FN events (55%) were observed in cycle 1. One-half of high risk patients who did not receive primary CSF prophylaxis in cycle 1 received CSF during subsequent cycles following a neutropenic event. Conclusions: Our model for predicting neutropenic complications can identify patients at high individual risk for severe neutropenia in cycle 1 or FN in the first 4 cycles of chemotherapy when receiving intermediate risk chemotherapy. This analysis emphasizes the potential value of determining an individual patient's risk of chemotherapy complications based on a validated risk model. Disclosures: Lyman: Amgen: Research Funding. Crawford:Amgen: Consultancy, Honoraria, Research Funding. Dale:Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Kuderer:Amgen: Research Funding." @default.
• W2574201053 created "2017-01-26" @default.
• W2574201053 creator A5015520404 @default.
• W2574201053 creator A5041299305 @default.
• W2574201053 creator A5073060840 @default.
• W2574201053 creator A5081181804 @default.
• W2574201053 creator A5089115491 @default.
• W2574201053 creator A5090143035 @default.
• W2574201053 date "2011-11-18" @default.
• W2574201053 modified "2023-09-28" @default.
• W2574201053 title "Personalizing Cancer Supportive Care: Predicting Neutropenic Complications in Patients Receiving Intermediate Risk Cancer Chemotherapy" @default.
• W2574201053 doi "https://doi.org/10.1182/blood.v118.21.1022.1022" @default.
• W2574201053 hasPublicationYear "2011" @default.
• W2574201053 type Work @default.
• W2574201053 sameAs 2574201053 @default.
• W2574201053 citedByCount "2" @default.
• W2574201053 countsByYear W25742010532015 @default.
• W2574201053 countsByYear W25742010532016 @default.
• W2574201053 crossrefType "journal-article" @default.
• W2574201053 hasAuthorship W2574201053A5015520404 @default.
• W2574201053 hasAuthorship W2574201053A5041299305 @default.
• W2574201053 hasAuthorship W2574201053A5073060840 @default.
• W2574201053 hasAuthorship W2574201053A5081181804 @default.
• W2574201053 hasAuthorship W2574201053A5089115491 @default.
• W2574201053 hasAuthorship W2574201053A5090143035 @default.
• W2574201053 hasConcept C121608353 @default.
• W2574201053 hasConcept C126322002 @default.
• W2574201053 hasConcept C141071460 @default.
• W2574201053 hasConcept C143998085 @default.
• W2574201053 hasConcept C2776694085 @default.
• W2574201053 hasConcept C2777063308 @default.
• W2574201053 hasConcept C2778336483 @default.
• W2574201053 hasConcept C2778850193 @default.
• W2574201053 hasConcept C2781413609 @default.
• W2574201053 hasConcept C71924100 @default.
• W2574201053 hasConceptScore W2574201053C121608353 @default.
• W2574201053 hasConceptScore W2574201053C126322002 @default.
• W2574201053 hasConceptScore W2574201053C141071460 @default.
• W2574201053 hasConceptScore W2574201053C143998085 @default.
• W2574201053 hasConceptScore W2574201053C2776694085 @default.
• W2574201053 hasConceptScore W2574201053C2777063308 @default.
• W2574201053 hasConceptScore W2574201053C2778336483 @default.
• W2574201053 hasConceptScore W2574201053C2778850193 @default.
• W2574201053 hasConceptScore W2574201053C2781413609 @default.
• W2574201053 hasConceptScore W2574201053C71924100 @default.
• W2574201053 hasLocation W25742010531 @default.
• W2574201053 hasOpenAccess W2574201053 @default.
• W2574201053 hasPrimaryLocation W25742010531 @default.
• W2574201053 hasRelatedWork W1909026420 @default.
• W2574201053 hasRelatedWork W1971513046 @default.
• W2574201053 hasRelatedWork W1989925579 @default.
• W2574201053 hasRelatedWork W2026417873 @default.
• W2574201053 hasRelatedWork W2057655957 @default.
• W2574201053 hasRelatedWork W2074790028 @default.
• W2574201053 hasRelatedWork W2091900888 @default.
• W2574201053 hasRelatedWork W2128830492 @default.
• W2574201053 hasRelatedWork W2215157211 @default.
• W2574201053 hasRelatedWork W2317582407 @default.
• W2574201053 hasRelatedWork W2320512253 @default.
• W2574201053 hasRelatedWork W2413047870 @default.
• W2574201053 hasRelatedWork W2418179624 @default.
• W2574201053 hasRelatedWork W2587133380 @default.
• W2574201053 hasRelatedWork W2588945616 @default.
• W2574201053 hasRelatedWork W2736111722 @default.
• W2574201053 hasRelatedWork W2892571161 @default.
• W2574201053 hasRelatedWork W3009779957 @default.
• W2574201053 hasRelatedWork W3083763733 @default.
• W2574201053 hasRelatedWork W3003482833 @default.
• W2574201053 isParatext "false" @default.
• W2574201053 isRetracted "false" @default.
• W2574201053 magId "2574201053" @default.
• W2574201053 workType "article" @default.